You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

Investigational Drug Information for Chidamide


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Chidamide?

Chidamide is an investigational drug.

There have been 156 clinical trials for Chidamide. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2019.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Lymphoma, T-Cell, Peripheral. The leading clinical trial sponsors are Sun Yat-sen University, Chinese PLA General Hospital, and Chipscreen Biosciences, Ltd.

There are five US patents protecting this investigational drug and twenty-eight international patents.

Recent Clinical Trials for Chidamide
TitleSponsorPhase
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell LymphomaJiangsu HengRui Medicine Co., Ltd.Phase 3
Tucidinostat Plus Apatinib for Advanced OsteosarcomaWuhan Union Hospital, ChinaPhase 2
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell LymphomaDongguan People's HospitalPhase 2

See all Chidamide clinical trials

Clinical Trial Summary for Chidamide

Top disease conditions for Chidamide
Top clinical trial sponsors for Chidamide

See all Chidamide clinical trials

US Patents for Chidamide

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Chidamide ⤷  Sign Up 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, CN) ⤷  Sign Up
Chidamide ⤷  Sign Up Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, CN) ⤷  Sign Up
Chidamide ⤷  Sign Up Histone deacetylase inhibitors Orchid Chemicals & Pharmaceuticals Limited (Chennai, IN) ⤷  Sign Up
Chidamide ⤷  Sign Up Crystal form of chidamide, preparation method and use thereof SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (Shenzhen, Guangdong, CN) ⤷  Sign Up
Chidamide ⤷  Sign Up Agents for killing HIV-1-infected cells and application thereof KAGOSHIMA UNIVERSITY (Kogoshima-Shi, Kagoshima, JP) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Chidamide

Drugname Country Document Number Estimated Expiration Related US Patent
Chidamide Australia AU2008309269 1989-12-31 ⤷  Sign Up
Chidamide Canada CA2702536 1989-12-31 ⤷  Sign Up
Chidamide European Patent Office EP2205563 1989-12-31 ⤷  Sign Up
Chidamide Japan JP2011501746 1989-12-31 ⤷  Sign Up
Chidamide Japan JP2014144947 1989-12-31 ⤷  Sign Up
Chidamide World Intellectual Property Organization (WIPO) WO2009047615 1989-12-31 ⤷  Sign Up
Chidamide Australia AU2012395573 2032-11-27 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.